On September 2nd, the 34th China Pharmaceutical Industry Information Annual Conference organized by China National Pharmaceutical Industry Information Center (PHIIC) took place in Chengdu. At the conference, the list of China’s Top 100 Pharmaceutical Companies (“the Top 100 List”) in 2016 was unveiled. Hansoh Pharma ranked 23rd on the list, with constantly robust growth momentum.
The 2017 list of China’s Top 20 Industrial Companies by Pharmaceutical R&D Pipeline was also released at the conference. Hansoh Pharma won the second place.
The Top 100 List was a highly-coveted award in the pharmaceutical industry. Its ranking was based on the China Medical Statistical Yearbook, an official and authoritative publication that mirrored the actual performance of China’s pharmaceutical industry. According to PHIIC’s statistics and analytics, the 2016 Top 100 companies maintained their rapid growth momentum. By comparable metrics, the accumulative revenue of 2016 Top 100 pharmaceutical companies was RMB680.9 billion, representing 11.1% YOY growth and 1.2% higher than the industry average (9.9%). It’s noteworthy that the threshold revenue for making the list was also lifted to RMB2.4billion, which means the average size of this exclusive club members is growing fast.
The focus on innovation and branding development played a non-negligible role in securing Hansoh Pharma’s place on the two aforementioned lists. In its 22-year history, Hansoh Pharma was always committed to its mission of serving the society and building a healthy world. It successfully became a market leader in multiple key therapeutic areas such as oncology, CNS, anti-infectives, diabetes, cardiovascular, and gastrointestinal areas. Hansoh also actively made inroads into the mainstream markets in Europe and America and sought foreign partnership so as to advance its internationalization progress and its ambition to be a world-class innovator drugs producer. Hansoh Pharma’s overall prowess was widely-recognized among its peers.
Going forward, Hansoh Pharma will continue to work towards the goal of “Outstanding Chinese Enterprises and Powerful Chinese Manufacturers” and contribute to China’s healthcare industry and the public health.
